/image%2F6014638%2F20201113%2Fob_93f211_nasal-drug-delivery-technology.jpg)
In 2018, the global Nasal Drug Delivery Technology market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.
This report focuses on the global Nasal Drug Delivery Technology status, future forecast, growth opportunity, key market and key players.
The study objectives are to present the Nasal Drug Delivery Technology development in United States, Europe and China.Report Sample includes:- Table of Contents- List of Tables & Figures- Charts- Research MethodologyGet FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-nasal-drug-delivery-technology-2019-2025-62 The key players covered in this studyMerck & Co., Inc.Novartis AGGlaxosmithkline PLCJohnson & Johnson Services, Inc.Pfizer Inc.3MBecton, Dickinson and CompanyAegis Therapeutics LLCAptargroup, Inc.AstrazenecaMarket segment by Type, the product can be split into SpraysDrops & LiquidsPowdersGelsMarket segment by Application, split into Allergic And Non-allergic RhinitisNose CongestionVaccinationOther Therapeutic ApplicationsMarket segment by Regions/Countries, this report covers United StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South AmericaThe study objectives of this report are: To analyze global Nasal Drug Delivery Technology status, future forecast, growth opportunity, key market and key players.To present the Nasal Drug Delivery Technology development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.In this study, the years considered to estimate the market size of Nasal Drug Delivery Technology are as follows: History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/global-nasal-drug-delivery-technology-2019-2025-62 CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170Email: help@24marketreports.comFollow Us On linkedin :- https://www.linkedin.com/company/24-market-reports
The overuse of nasal sprays results in various complications, such as irritation in the nasal mucosa, dryness within the nose, temporary burning sensation, and runny nose.
Thus, the continuous use of these sprays may render the blood vessels to be less responsive to the medication.Also, overuse of nasal sprays usually causes addiction among patients, which may lead to serious long-term conditions such as chronic sinusitis.The global nasal drug delivery technology market is projected to reach USD 64.20 billion by 2021 from USD 44.00 billion in 2016, at a CAGR of 6.5%.
Nasal Drug Delivery Technology Market by Dosage Form (Nasal Drops, Sprays, Powder, Gel), System (Multidose, Unit Dose, BI-Dose), Therapeutic Applications (Rhinitis, Congestion, Vaccinations), End User (Hospitals, Homecare) – Global Forecast to 2021.According to the U.S. Department of Health & Human Services, in 2014, there were 29.4 million adults diagnosed with sinusitis in the U.S.; this represented 12.3% of thetotal population in the country.
These drawbacks are expected to limit the growth of the nasal drug delivery technology market (specifically for nasal sprays).Increasing patient preference for nasal drug delivery as a result of easy administration & better efficacy and growing adoption of self-administration practices are some of the major factors driving the growth of the nasal drug delivery technology market.
Furthermore, growth among over-the-counter nasal drugs and increasing focus on alternative routes of drug delivery such as nasal drug delivery offer significant growth opportunities for player operating in the market.
On the basis of therapeutic application, the market is segmented into allergic and non-allergic rhinitis, nasal congestion, vaccination, and other therapeutic applications (osteoporosis, pain management, and sexual dysfunction).The allergic and non-allergic rhinitis segment is expected to register the highest CAGR during the forecast period.
